Ingestible Device for Targeted Cecum Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for gastrointestinal diseases, such as inflammatory bowel disease, face challenges in delivering therapeutic drugs specifically to the gastrointestinal tract, particularly to the cecum, due to difficulties in developing devices that can safely and effectively transport and release drugs at the desired location within the body.
Innovation Solution
The development of ingestible devices equipped with a housing, a reservoir containing an integrin inhibitor, and a release mechanism that allows for autonomous or triggered release of the therapeutic agent in the cecum, enabling localized treatment with improved bioavailability and reduced systemic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If therapeutic drugs are administered orally for gastrointestinal diseases, then the treatment can be simplified and patient compliance improved, but the drug cannot be delivered specifically to the cecum and may be contaminated or digested in the stomach
Solution Approach 1:
The device is segmented into functional modules: an ingestible housing, a drug reservoir, a release mechanism triggered by magnetic fields, and navigation components. This segmentation allows the device to be swallowed whole while enabling precise drug release at the cecum through external magnetic triggering, combining ease of oral administration with precise targeted delivery.
2Manufacturing precision
If a device is developed to transport and release drugs specifically in the cecum, then delivery precision and drug engagement at target site are improved, but the device complexity increases and safety concerns arise from physical entry into the body
Solution Approach 1:
An external magnetic field serves as an intermediary to trigger drug release from the ingestible device. The magnetic field penetrates the body wall without physical contact, activating the release mechanism in the cecum through magnetic coupling. This intermediary approach enables precise targeted delivery while avoiding the complexity and safety risks of surgically implantable devices with physical access to the cecum.
3Quantity of substance
If therapeutic drugs are delivered systemically, then the drug can reach the target site, but the bioavailability at the site of injury is reduced and systemic toxicity increases
Solution Approach 1:
The device delivers drug locally at the cecum through targeted release triggered by external magnetic fields. The drug is contained in a reservoir within the ingestible device and released only when the device reaches the cecum, creating high local concentration at the disease site while minimizing systemic exposure. This local quality approach increases bioavailability at the target site and reduces systemic toxicity compared to conventional systemic administration.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an integrin inhibitor. In an exemplary embodiment, a pharmaceutical formulation that comprises the medicaments is released from an ingestible device at a location in the gastrointestinal tract that is proximate to one or more sites of disease.